MedTrace Logo

An Bioequivalence Study of Loxoprofen Sodium Patches in Healthy Volunteers

NCT06510413 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-07-19

No results posted yet for this study

Summary

This study was a single-center, randomized, open-label, two-agent, two-cycle, double-cross bioequivalence trial.

Conditions

Interventions

DRUG

Loxoprofen Sodium Patches(reference product)

Single dose of one patch in each period; Apply for 24 hours each time

DRUG

Loxoprofen Sodium Patches(test product )

Single dose of one patch in each period; Apply for 24 hours each time

Sponsors & Collaborators

  • Frontier Biotechnologies Inc.

    lead INDUSTRY

Principal Investigators

  • Cheng Yao · Frontier Biotechnologies Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2024-08-31
Completion
2024-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06510413 on ClinicalTrials.gov